OGEN - Oragenics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.4874
-0.0596 (-10.90%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.5470
Open0.5200
Bid0.4777 x 1000
Ask0.0000 x 900
Day's Range0.4800 - 0.5300
52 Week Range0.3800 - 3.7400
Volume1,570,979
Avg. Volume1,323,743
Market Cap22.479M
Beta (3Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)-0.6450
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Oragenics, Inc. to Present Data on Its Peptide Synthesis Platform at the American Peptide Symposium

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces it will be presenting at the American Peptide Symposium on their novel peptide synthesis platform for its lantibiotic pipeline. The presentation is scheduled on Wednesday, June 26, 2019, at the American Peptide Symposium in the Sierra Ballroom of the Monterey Conference Center in Monterey, Calif. Presented by Dr. Jae H. Park, this work demonstrates the peptide synthesis platform developed using orthogonally-protected lanthionine building blocks.

  • Business Wire10 days ago

    Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of a collaborative study investigating an additional mechanism of action of the company’s lantibiotic compounds, which shows the formation of water permeating pores across bacterial cell membranes. This novel mechanism of action is believed to cause disruption of the bacterial membranes and contribute to our compounds’ antimicrobial mechanism of action.

  • Zacks Small Cap Research20 days ago

    OGEN: New Pre-Clinical Data Shows Lantibiotic OG253 Safe and Well Tolerated…

    On May 20, 2019, Oragenics, Inc. (OGEN) announced that the 80th patient has been enrolled in the company’s ongoing Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). In addition, the World Health Organization provided the company with the generic name dapatifagene navolactibac for AG013. The trefoil factor family (TFF) is a family of three different peptides secreted by epithelial cells of the gastrointestinal tract in response to injury (Hoffman, 2004).

  • Business Wirelast month

    Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis

    “We continue to increase the number of clinical sites across the globe with 48 of the 61 identified clinical sites actively enrolling patients for our Phase 2 clinical trial of AG013,” stated Alan Joslyn, Ph.D., President and Chief Executive Officer of Oragenics, Inc. “In the meantime, we are pleased to have an agreed upon generic designation for AG013, which will now also be referred to as dapatifagene navolactibac, to allow us a more specific way of referring to the compound moving forward.

  • Business Wirelast month

    Newly Published Preclinical Data on Oragenics, Inc.’s Lantibiotic Compound Demonstrates Tolerability and Compartmentalization to the GI Tract

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the publication of preclinical data of the company’s lantibiotic compound OG253, a predecessor to its current lead lantibiotics compound OG716, when administered in animal models in the July 2019 peer review journal, Toxicology and Applied Pharmacology (https://doi.org/10.1016/j.taap.2019.04.019).

  • Introducing Oragenics (NYSEMKT:OGEN), The Stock That Collapsed 98%
    Simply Wall St.2 months ago

    Introducing Oragenics (NYSEMKT:OGEN), The Stock That Collapsed 98%

    Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for those who held Oragenics, Inc. (NYSEMKT:OG...

  • Zacks Small Cap Research3 months ago

    OGEN: 60th Patient Enrolled into Phase 2 Trial of AG013; Data in 1H2020…

    On March 15, 2019, Oragenics, Inc. (OGEN) announced that the 60th patient has been enrolled in the company’s ongoing Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactis strain that contains the coding sequence for human trefoil family factor 1 (hTFF1), which is continually secreted by the bacteria. The Phase 2 trial (NCT03234465) is expected to enroll approximately 160-180 subjects with head and neck cancer receiving chemotherapy and radiation who will receive either AG013 (2.0 x 1011 CFU) or placebo administered three times a day over 7-9 weeks (depending on the subject’s treatment plan).

  • Business Wire3 months ago

    Oragenics, Inc. to Present at Spring Investor Summit on April 1, 2019

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at Spring Investor Summit on April 1, 2019 at 1:00 PM ET as part of Track 1 at The Essex House in New York City. We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries.

  • Business Wire3 months ago

    Oragenics, Inc. Enters into Collaboration with Florida International University to Expand Its Pipeline of Lantibiotics

    Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the initiation of a collaboration with Florida International University (FIU) to create computational models of the company’s lantibiotic compounds interacting with bacterial membranes and Lipid II, the target of Oragenics’ compounds with the ultimate goal of expanding the lantibiotic pipeline.

  • Business Wire3 months ago

    Oragenics Announces Closing of $12.5 Million Underwritten Public Offering

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced the closing of its previously announced underwritten public offering of 16,666,668 shares of common stock, short-term warrants to purchase up to 8,333,334 shares of common stock, and long-term warrants to purchase up to 8,333,334 shares of common stock, at a price to the public of $0.75 per share and accompanying warrants. Oragenics expects to receive gross proceeds of approximately $12.5 million from the offering. H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

  • Business Wire3 months ago

    Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced the pricing of its previously announced underwritten public offering of 16,666,668 shares of common stock, short-term warrants to purchase up to 8,333,334 shares of common stock, and long-term warrants to purchase up to 8,333,334 shares of common stock, at a price to the public of $0.75 per share and accompanying warrants. Oragenics expects to receive gross proceeds of approximately $12.5 million from the offering. Each short-term warrant will have an exercise price of $0.75 per share of common stock, will be immediately exercisable, and will expire on the earlier of (1) the eighteen month anniversary of the date of issuance and (2) twenty-one trading days following the Company’s release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013.

  • Benzinga3 months ago

    6 Stocks Moving In Wednesday's After-Hours Session

    Gainers: Herman Miller, Inc. (NASDAQ: MLHR ) shares are up 4 percent after reporting a third-quarter earnings beat. Adjusted earnings came in at 64 cents per share, beating estimates by 4 cents. Sales ...

  • Business Wire3 months ago

    Organics Announces Proposed Underwritten Public Offering

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has commenced a proposed underwritten public offering of common stock of the Company, together with warrants to purchase shares of common stock. In addition, the Company expects to grant the underwriter of the offering, a 30-day option to purchase additional shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • ACCESSWIRE3 months ago

    Four Healthcare Stocks Heating Up On Monday

    Whereas other sectors may cut corners or decrease quality in the name of revenue, healthcare companies do not have this luxury. As consumers, we expect the healthcare industry to create products and treatments to help us feel better and to invest in future technologies so that medical professionals can assist their patients in preventive medicine, not just reactive care. The healthcare industry has demonstrated in the first few months of 2019 that these expectations are more than fair, and if companies in the sector continue to prove their aptitude for helping patients, this may catalyze investor interest in the future.

  • Business Wire3 months ago

    Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the enrollment of the 60th patient in its Phase 2 double blind, placebo controlled clinical trial of AG013 (NCT03234465). Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries.

  • Business Wire3 months ago

    Oragenics Inc. to Attend the Roth Capital 31st Annual Growth Conference March 17 - 19, 2019

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced that Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc. will attend the Roth Capital 31st Annual Growth Conference. The conference will be held at the Ritz-Carlton Hotel in Laguna Nigel, CA. We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.

  • How Much Are Oragenics, Inc. (NYSEMKT:OGEN) Insiders Spending On Buying Shares?
    Simply Wall St.4 months ago

    How Much Are Oragenics, Inc. (NYSEMKT:OGEN) Insiders Spending On Buying Shares?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We often see insiders buying up shares in companies thatRead More...

  • Zacks Small Cap Research5 months ago

    OGEN: New Preclinical Research Confirms OG716 Potential in Treating C. Difficile Infection…

    On January 28, 2019, Oragenics, Inc. (OGEN) announced the publication of new preclinical data for the company’s lead lantibiotic development product, OG716, in the peer reviewed journal Antimicrobial Agents and Chemotherapy. Lantibiotics are a class of peptide antibiotics that are produced by certain Gram-positive bacterial strains. The compounds range in size from 22 to 34 amino acids and typically go through a number of posttranslational modifications that results in novel serine and threonine derivatives, multiple types of sulfhydryl bonds, and the presence of the uncommon amino acids lanthionine (Lan) and B-methyllanthionine (MeLan), from which the lantibiotic name is derived.

  • Business Wire5 months ago

    Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of a preclinical study using the lead compound from its lantibiotics program, OG716, in the peer reviewed journal, Antimicrobial Agents and Chemotherapy. The preclinical study demonstrated that following oral administration of the maximum feasible dose of OG716 in hamster models, there were no observable toxicities nor observable side effects, nor was there any effect on intestinal motility. Lantibiotics, including OG716, are a novel class of peptide antibacterial compounds naturally produced by a variety of Gram-positive bacteria.

  • Business Wire5 months ago

    Oragenics Inc. to Present at NobleCon15 on January 28, 2019

    Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), announced today that Alan Joslyn, Ph.D., president and CEO of Oragenics will be a featured presenter at NobleCon15 - Noble Capital Markets’ Fifteenth Annual Investor Conference on January 28th at 10:30 AM Eastern Standard Time. A high-definition, video webcast of the presentation will be available the following day on Oragenics' web site https://www.oragenics.com/, and as part of a complete catalog of presentations available at Noble Capital Markets’ websites: www.noblecapitalmarkets.com, and www.nobleconference.com. We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.

  • ACCESSWIRE7 months ago

    Oragenics Fast Track Drug AG013 Going into Phase II Clinicals, Pipeline Review

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Oragenics, Inc. (OGEN) a company focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. OGEN's product AG013, which has been granted Fast Track designation with the U.S. Food and Drug Administration and orphan drug status in Europe, is an Intrexon Actobiotics therapeutic candidate formulated to deliver the therapeutic molecule, human Trefoil Factor 1, to the mucosal tissues in the oral cavity in a convenient oral rinsing solution.

  • ACCESSWIRE7 months ago

    Today's Research Reports on Trending Tickers: Oragenics and Intec Pharma

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / There was no news to explain the new high that Intec Pharma hit on Friday but Oragenics surged over 30% after announcing the publication of a research paper last week. Oragenics, Inc. shares closed up 33.66% on Friday with around 24.7 million shares traded. It was early last week that the company announced the publication of a research paper called "Blueprints for the rational design of therapeutic mutacin 1140 variants." The study focused on structure-activity relationships of the lantibiotic Mutacin 1140 (MU1140) that expand the “drugability” of the MU1140 pipeline.

  • Business Wire7 months ago

    Oragenics, Inc. Announces Publication Detailing the Development of Blueprints for Designing a New Class of Anti-Infectives

    Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced the publication of a research paper titled “Blueprints for the rational design of therapeutic mutacin 1140 variants,” in Chemical Biology & Drug Design (CBDD). The company has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries, which allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

  • ACCESSWIRE7 months ago

    Oragenics, Inc. to Present at the 11th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 26, 2018 / Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM) today announced that it will be presenting at the 11th annual LD Micro Main Event on Thursday, December 6th at 9:30 AM PST, 12:30 PM EST. Dr. Alan Joslyn, Chief Executive Officer of Oragenics, Inc. will be presenting and meeting with investors. The LD Micro Main Event will take place December 4th, 5th, and 6th, in Los Angeles at the Luxe Sunset Bel Air Hotel, will feature 250 companies, and will be attended by over 1,200 individuals.

  • GlobeNewswire7 months ago

    Recent Analysis Shows Liberty Global, New Oriental Education & Technology Group, Platinum Group Metals, Asure Software, Oragenics, and MGE Energy Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.